Bones and groans: The basics of osteoporosis and the use of bone markers

Laboratory Medicine

Volumn 38, Issue 5, 2007, Pages 273-278

  Hammett Stabler, Catherine ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149465613     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/NGCGAFWQFNBKVTDQ     Document Type: Article

References (48)

1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-1767.
2. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004.
3. National Osteoporosis Foundation. America's bone health: The state of osteoporosis and low bone mass in our nation. NOF 2002.
4. Zingmond DS, Melton LJ, Silverman SL. Increasing hip fracture incidence in California Hispanics, 1983 to 2000. Osteoporos Int. 2004;15:603-610.
5. Tortolani PJ, McCarthy EF, Sponseller PD. Bone mineral density deficiency in children. J Am Acad Orthop Surg. 2002;10:57-66.
6. Stallings VA. Calcium and bone health in children: A review. Am J Thera. 1997;4:259-273.
7. Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13:323-330.
8. Parfitt AM. What is the normal rate of bone remodeling? Bone. 2004;35:1-3.
9. Blair HC, Carrington JL. Bone cell precursors and the pathophysiology of bone loss. Ann NY Acad Sci. 2006;1068:244-249.
10. Li Z, Kong K, Qi W. Osteoclast and its roles in calcium metabolism and bone development and remodeling. Biochem Biophys Res Commun. 2006;343:345-350.
11. Canalis E, Deregowski V, Pereira RC, et al. Signals that determine the fate of osteoblastic cells. J Endocrinol Invest. 2005;28:S3-S7.
12. Parfill AM. Misconceptions V - Activation of osteoclasts is the first step in the bone remodeling cycle. Bone. 2006;39:1170-1172.
13. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318-3325.
14. Jones ME, Boon WC, Proietto J, et al. Of mice and men: The evolving phenotype of aromatase deficiency. Trends Endocrinol Metab. 2006;17:55-64.
15. Pernow Y, Granberg B, Saaf M, et al. Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int. 2006;78:90-97.
16. Kennel KA, Riggs BL, Achenbach SJ, et al. Role of parathyroid hormone in mediating age-related changes in bone resorption in men. Osteoporos Int. 2003;14:631-636.
17. Seeman E, Delmas PD. Bone quality - The material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250-2261.
18. Ralston SH. Genetic determinants of osteoporosis. Curr Opin Rheumatol. 2005;17:475-479.
19. Chavassieux PM, Delmas PD. Bone remodeling: Biochemical markers or bone biopsy? J Bone Miner Res. 2006;21:178-179.
20. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep. 2005;3:103-110.
21. Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin. 2005;21:1015-1026.
22. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81:662-672.
23. World Health Organization (WHO). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. [Technical report series 843]. Geneva: WHO, 1994.
24. Leib ES, Lenchik L, Bilezikian JP, et al. International Society for Clinical Densitometry Scientific Policy Development Conference. Justification and Methodology. J Clin Densitom. 2002;5:S5-S10.
25. Miller PD, Njeh CF, Jankowski LG, et al. What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? J Clin Densitom. 2002;5:S39-S45.
26. Placide J, Martens MG. Comparing screening methods for osteoporosis. Curr Womens Health Rep. 2003;3:207-210.
27. Woitge HW, Seibel MJ, Ziegler R. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem. 1996;42:1796-1804.
28. Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr Metab Care. 2001;4:483-487.
29. Srivastava AK, Mohan S, Singer FR, et al. A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone. 2002;31:62-69.
30. Cloos PA, Christgau S. Characterization of aged osteocalcin fragments derived from bone resorption. Clin Lab. 2004;50:585-598.
31. Orum O, Hansen M, Jensen CH, et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone. 1996;19:157-163.
32. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res. 1992;7:1243-1250.
33. Halleen JM, Ylipahkala H, Alatalo SL, et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int. 2002;71:20-25.
34. Vesper HW, Smith SJ, Audain C, et al. Comparison study of urinary pyridinoline and deoxypyridinoline measurements in 13 US laboratories. Clin Chem. 2001;47:2029-2031.
35. Rubinacci A, Melzi R, Zampino M, et al. Total and free deoxypyridioline after acute osteoclast activit inhibition. Clin Chem. 1999;45:1510-1516.
36. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med. 1997;157:1241-1245.
37. Schober EA, Breusch SJ, Schneider U. Instability and variability of urinary telopeptides and free crosslinks. Clin Chim Acta. 2002;324:73-79.
38. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31:57-61.
39. Szule P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2002;11:281-294.
40. Mora S, Pitukeheewanont P, Kaufman FR, et al. Biochemical markers of bone turnover and the volume and density of bone in children at different stages of sexual development. J Bone Miner Res. 1999;14:1664-1671.
41. Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab. 1996;81:3366-3371.
42. Fall PM, Kennedy D, Smith JA, et al. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int. 2000; 11:481-485.
43. Minisola S, Dionisi S, Pacitti T, et al. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorder affecting bone. Osteoposos Int. 2002;13:171-175.
44. Worsfold M, Powell DE, Jones TJW, et al. Assessment of urinary bone markers for monitoring treatment of osteoporosis. Clin Chem. 2004;12:2263-2270.
45. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2005;90:2762-2767.
46. Weisman SM, Matkovic V. Potential use of biochemical markers of bone turnover for assessing the effect of calcium supplementation and predicting fracture risk. Clin Ther. 2005;27:299-308.
47. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962-970.
48. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both? Am J Med. 2006;119:S25-S31.